These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

636 related articles for article (PubMed ID: 36546712)

  • 1. Heart failure: an update from the last years and a look at the near future.
    Riccardi M; Sammartino AM; Piepoli M; Adamo M; Pagnesi M; Rosano G; Metra M; von Haehling S; Tomasoni D
    ESC Heart Fail; 2022 Dec; 9(6):3667-3693. PubMed ID: 36546712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decongestion With Acetazolamide in Acute Decompensated Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction: A Prespecified Analysis From the ADVOR Trial.
    Martens P; Dauw J; Verbrugge FH; Nijst P; Meekers E; Augusto SN; Ter Maaten JM; Damman K; Mebazaa A; Filippatos G; Ruschitzka F; Tang WHW; Dupont M; Mullens W
    Circulation; 2023 Jan; 147(3):201-211. PubMed ID: 36335479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium-Glucose Cotransporter 2 Inhibitors Among Heart Failure With Mildly Reduced and Preserved Ejection Fraction.
    Cheng JWM; Colucci V; Kalus JS; Spinler SA
    Ann Pharmacother; 2023 Nov; 57(11):1291-1301. PubMed ID: 36800904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium-glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis.
    Wang Y; Gao T; Meng C; Li S; Bi L; Geng Y; Zhang P
    Eur J Med Res; 2022 Dec; 27(1):314. PubMed ID: 36581880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acetazolamide in Acute Decompensated Heart Failure with Volume Overload.
    Mullens W; Dauw J; Martens P; Verbrugge FH; Nijst P; Meekers E; Tartaglia K; Chenot F; Moubayed S; Dierckx R; Blouard P; Troisfontaines P; Derthoo D; Smolders W; Bruckers L; Droogne W; Ter Maaten JM; Damman K; Lassus J; Mebazaa A; Filippatos G; Ruschitzka F; Dupont M;
    N Engl J Med; 2022 Sep; 387(13):1185-1195. PubMed ID: 36027559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S
    Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial.
    Felker GM; Solomon SD; Claggett B; Diaz R; McMurray JJV; Metra M; Anand I; Crespo-Leiro MG; Dahlström U; Goncalvesova E; Howlett JG; MacDonald P; Parkhomenko A; Tomcsányi J; Abbasi SA; Heitner SB; Hucko T; Kupfer S; Malik FI; Teerlink JR
    JAMA Cardiol; 2022 Jan; 7(1):26-34. PubMed ID: 34643642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population.
    Thorvaldsen T; Ferrannini G; Mellbin L; Benson L; Cosentino F; McMurray JJV; Dahlström U; Lund LH; Savarese G
    J Card Fail; 2022 Jul; 28(7):1050-1062. PubMed ID: 35550428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining Loop and Thiazide Diuretics Across the Left Ventricular Ejection Fraction Spectrum: The CLOROTIC Trial.
    Sánchez-Marteles M; Garcés-Horna V; Morales-Rull JL; Casado J; Carrera-Izquierdo M; Conde-Martel A; Dávila-Ramos MF; Llácer P; Salamanca-Bautista P; Ruiz R; Aramburu-Bodas O; Formiga F; Manzano L; Trullàs JC
    JACC Heart Fail; 2024 Oct; 12(10):1719-1730. PubMed ID: 38934966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial.
    Chatur S; Vaduganathan M; Claggett B; Vardeny O; Desai AS; Jhund PS; de Boer RA; Lam CSP; Kosiborod MN; Shah SJ; Martinez F; Inzucchi SE; Hernandez AF; Haddad T; Mitter SS; Miao ZM; Petersson M; Maria Langkilde A; McMurray JJV; Solomon SD
    Eur Heart J; 2023 Aug; 44(31):2930-2943. PubMed ID: 37220093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empagliflozin: A Review in Symptomatic Chronic Heart Failure.
    Frampton JE
    Drugs; 2022 Nov; 82(16):1591-1602. PubMed ID: 36374374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Meta-analysis.
    Xiang B; Zhang R; Wu X; Zhou X
    JAMA Netw Open; 2022 Sep; 5(9):e2231963. PubMed ID: 36125813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A year in heart failure: an update of recent findings.
    Stretti L; Zippo D; Coats AJS; Anker MS; von Haehling S; Metra M; Tomasoni D
    ESC Heart Fail; 2021 Dec; 8(6):4370-4393. PubMed ID: 34918477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dronedarone for the treatment of atrial fibrillation with concomitant heart failure with preserved and mildly reduced ejection fraction: a post-hoc analysis of the ATHENA trial.
    Vaduganathan M; Piccini JP; Camm AJ; Crijns HJGM; Anker SD; Butler J; Stewart J; Braceras R; Albuquerque APA; Wieloch M; Hohnloser SH
    Eur J Heart Fail; 2022 Jun; 24(6):1094-1101. PubMed ID: 35293087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acetazolamide in Decompensated Heart Failure with Volume Overload trial (ADVOR): baseline characteristics.
    Mullens W; Dauw J; Martens P; Meekers E; Nijst P; Verbrugge FH; Chenot F; Moubayed S; Dierckx R; Blouard P; Derthoo D; Smolders W; Ector B; Hulselmans M; Lochy S; Raes D; Van Craenenbroeck E; Vandekerckhove H; Hofkens PJ; Goossens K; Pouleur AC; De Ceuninck M; Gabriel L; Timmermans P; Prihadi EA; Van Durme F; Depauw M; Vervloet D; Viaene E; Vachiery JL; Tartaglia K; Ter Maaten JM; Bruckers L; Droogne W; Troisfontaines P; Damman K; Lassus J; Mebazaa A; Filippatos G; Ruschitzka F; Dupont M
    Eur J Heart Fail; 2022 Sep; 24(9):1601-1610. PubMed ID: 35733283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF.
    Teerlink JR; Diaz R; Felker GM; McMurray JJV; Metra M; Solomon SD; Legg JC; Büchele G; Varin C; Kurtz CE; Malik FI; Honarpour N
    JACC Heart Fail; 2020 Apr; 8(4):329-340. PubMed ID: 32035892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lessons from a pre-specified meta-analysis of sodium-glucose cotransporter-2 (SGLT2) inhibitors in heart failure: Time for new clinical recommendations.
    Kotit S
    Glob Cardiol Sci Pract; 2023 May; 2023(2):e202314. PubMed ID: 37351098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chapter 3: Clinical Trials of Sodium-Glucose Co-Transporter-2 Inhibitors for Treatment of Heart Failure.
    Greene SJ; Butler J; Kosiborod MN
    Am J Med; 2024 Feb; 137(2S):S25-S34. PubMed ID: 38184323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial.
    Savarese G; Uijl A; Lund LH; Anker SD; Asselbergs F; Fitchett D; Inzucchi SE; Koudstaal S; Ofstad AP; Schrage B; Vedin O; Wanner C; Zannad F; Zwiener I; Butler J
    J Card Fail; 2021 Aug; 27(8):888-895. PubMed ID: 34364665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five-year mortality of heart failure with preserved, mildly reduced, and reduced ejection fraction in a 4880 Chinese cohort.
    Chen S; Huang Z; Liang Y; Zhao X; Aobuliksimu X; Wang B; He Y; Kang Y; Huang H; Li Q; Yao Y; Lu X; Qian X; Xie X; Liu J; Liu Y
    ESC Heart Fail; 2022 Aug; 9(4):2336-2347. PubMed ID: 35437939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.